Inhaled Insulin – A New Delivery for an Old Drug

Fantasia, Heidi Collins

doi:10.1111/1751-486x.12177

Cited by 6 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the inhaled insulin powder Afrezza ® , which has been marketed, can significantly reduce the incidence of hypoglycemia and relieve the pain of patients, the sales volume and the market feedback of Afrezza ® is unsatisfactory as well. The reason for the poor sales of Afrezza ® may be that people are still skeptical about the safety of insulin DPIs, and the price of the inhaler and its associated inhalation device is higher than that of insulin injection (Fantasia, 2015). Compared with Afrezza ® , this paper aims to optimize the preparation process of INS@FDKP-MPs by adopting a simpler and more convenient synthesis method to reduce the production cost, and by evaluating the properties of INS@FDKP-MPs, it is intended to construct an inhalable insulin preparation that is qualified in particle size, drug loading, hypoglycemic effect, and safety.…”

Section: Introductionmentioning

confidence: 99%

Preparation, characterization, and pharmacodynamics of insulin-loaded fumaryl diketopiperazine microparticle dry powder inhalation

Xia

Wang

et al. 2019

Drug Delivery

View full text Add to dashboard Cite

Purpose: With the increase of population aging and the proportion of overweight and obese, a growing number of people are suffering from diabetes. Insulin (INS) as the most widely used hypoglycemic agent was always chosen as the most effective treatment method of diabetes. In this study, fumaryl diketopiperazine (FDKP) was used as a carrier for the pulmonary delivery of insulin. Patients and methods: The INS-loaded FDKP microspheres (INS@FDKP-MPs) were prepared by spray drying and physicochemical properties (drug loading, particle size, flowability, moisture content, morphology, and crystalline state) were further investigated. Pharmacodynamics was investigated on diabetic model rats administrated by intratracheal insufflation. Results: The INS-loaded FDKP microspheres show satisfied flowability and in vitro deposition with FPF 50.2% and MMAD 3.45 ± 0.13 lm, and the blood glucose level was significantly decreased. Moreover, no inflammatory reaction was observed during the safety study. Conclusion: To sum up, the aim was to develop a non-injection system for insulin, INS@FDKP-MPs powder inhalation with high dose, low toxicity, and good lung deposition inhalation could rapidly decrease the blood glucose level without immune stimulation, which shows remarkably potential on diabetes treatment by pulmonary delivery route.

show abstract

Section: Introductionmentioning

confidence: 99%

Preparation, characterization, and pharmacodynamics of insulin-loaded fumaryl diketopiperazine microparticle dry powder inhalation

Xia

Wang

et al. 2019

Drug Delivery

View full text Add to dashboard Cite

show abstract

“…MannKind Corp.'s interestingly secured FDA approval for Afrezza on the 27th of June, 2014 [33]. With Afrezza, insulin is administered via the breath-powered, dry powder Gen2 inhaler [34] (also known as the DreamBoat inhaler) that provides ease of use and consistent, reproducible insulin delivery according to the company's claim.…”

Section: Introductionmentioning

confidence: 99%